GIP and type 2 diabetes mellitus: Tirzepatide, a novel agent belonging to the glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) class (dual GIP/GLP-1 RA), has also been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of type 2 diabetes.